Drugs / TG6050
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05788926 | Apr 2023 → Jun 2025 | non-small cell lung carcinoma | Transgene | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-08-27 | Transgene | Results Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC transgene.com ↗
The JITC paper reports that in addition to consistent multiplication and propagation of TG6050 in tumor cells, functional transgenes are expressed in the tumor with a sustained intratumoral accumulation of IL-12 and anti-CTLA-4 antibody. |
| 2023-04-17 | Transgene | Results Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR transgene.com ↗
These data demonstrate the ability of TG6050 to induce strong antitumor responses through the production of IL -12 and anti -CTLA4 antibody in the tumor and the induction of innate and adaptive immune responses. |
| 2023-01-06 | Transgene | Regulatory Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration transgene.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG6050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05788926 ↗ |
| Action | Inhibit | “an anti-CTLA4 antibody” NCT05788926 ↗ |
| Target | CTLA4 | “an anti-CTLA4 antibody” NCT05788926 ↗ |